Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial. (December 2020) - Ray, K.K.; Kallend, D.; Leiter, L.A.; Raal, F.J.; Koenig, W.; Jaros, M.J.; Schwartz, G.G.; Landmesser, U.; Wijngaard, P.L.; Wright, R.S.; Kastelein, J.J.